appreciate good our operator, results and you XXXX. thank business attention. Thank call morning to joining We quarter second conference for financial time discuss for and highlights you, the everyone everyone’s BioXcel and Therapeutics
today the Reina Officer; President Officer; Vince O'Neill, Chief of Senior Vice Development Officer; Clinical Joining Will call Chief Chief Kane, me are on Risinger, Development. Commercial Benabou, Medical and Rob
today. as today’s unable In is Steinhart, the committed and on U.S. leave implemented to currently every earlier our policy world earlier lives Michael of they spread join each to is CDC will still financial protecting us Connecticut in and – one absence Our accordance reviewing year, CFO, us. Richard our affect the this is and remain and Stanton, workers of his to and with medical uncertainty halting Controller, call. our Healthcare virus. the he will in the COVID-XX continues for creating we In be forever of results all Months on the employees. work-from-home State heroes a be
we elderly been continuing the have any to ongoing strict facilities, while practice implementing experienced staff accessing to to our protect fortunate to best determine this. rules monitoring have for of care employees. clinical slowly bringing and or our for to the the initiated trial. plan, in delays work of second in the the pandemic back number Except challenges that significant office planned We the not At quarter, are the end order we return of mitigating we operations impact our limited a
situation monitor closely and needed. updates to provide continue we as the However,
X I clinical BioXcel’s cannot commercial, most we neuroscience with one on of candidates: advance will starting are as to of clinical We know, follow our and offering. trials two We our history be we Phase and remain BXCLXXX tell BXCLXXX. you pivotal times in our pleased our you on the As is committed of a progress. to with successful investigation and positive development results off with two track in BXCLXXX. very from of plans many candidate the BXCLXXX lead this exciting how
acute reminder, a dexmedetomidine, of a or film for XXX in ecstatic which for treatment positive acute from call to I were disorder, of exploratory greater thin treatment agitation both proprietary BXCLXXX primary, reviewed month of SERENITY trials endpoint. achieving We like in As X secondary we is during to bipolar agitation. formulation would Phase also top-line detail the a and results, those the Dex, last recap with results and patients month. conference schizophrenia of the quickly announce last
similarly after PEC, XX In As Both XXX the or agitation. microgram, improvement X two clinically from scale, the trials change age. on XXX in primary validated significant of PEC to time X secondary trials and total the agitation placebo. the score score recall, objective at determine PEC impact as end demonstrated statistically meaningful were the to highly by arms XX effect baseline earliest early The minutes which you hours. matching the clinically highly significant at endpoints improvement lasting in degree receiving durable four in significant as reductions treatment. with double-blind was an to means primary, statistically BXCLXXX’s these for apparent quantify patients studies using PAN's with as was randomized patients, a Excitatory extremely The may designed in trials statistically of or benefit effect key agitation point of of important agitation hours and group an film meaningful trial, and the XXX each demonstrated a two of score. parallel either of rapid at years is XX were exploratory also placebo-controlled further SERENITY caregiver both the and a To to agitation confirm micrograms onset least was a reductions on patient. demonstrated measures Component total our
was BXCLXXX schizophrenia In could happier events. II. caregivers. tolerated with SERENITY of of the We safety as disorder well milestone terms profile, no adverse bipolar as for important I represents their it data with be patients serious and encouraging These well outcome not with an and
is our submitting of team the Allergan, plan Kane Reina neuroscience in to bringing hired developing of Officer Chief force. in In built preparation General to pre-NDA first expected U.S. Medical next and a as quarter Chief have commercialization Chief the we and former hires months develop have of including Officer, management FDA and experience Will team, Benabou Medicine FDA a and Commercial and in building products over Cognivue. and and look of Both medical scheduled Dr. hiring team to as markets needed, for potential the Will have meeting Reina’s prelaunch have with October We XX and BHCLXXX, Development infrastructure Officer an business focus by sales at will out be strategy. go-to-market managed in the extensive integral and Head our market the forward the the affairs XXXX. NDA the former the unit approval the
these is in highlight withdrawal well a the well initiate a trials disease. to the be candidate's SERENITY treatment This we in XXXX. And as from a are by ranging know, potential chronic dementia opens reduce are mechanism potential and for underlying from neuropsychiatric beneficial of later to preparing to year. delirium launch the an conditions helping for despite symptoms effective Phase II Furthermore, being patients this variety to BXCLXXX’s treatment results agitation BXCLXXX from the and opioid suffering of trial acute for already of prepared turn strong in We underway product will investigating agitation. you action
tolerable trial in this is dementia, an of adaptive PEC, Inventory. dose trial and Scale proof-ofXconcept and the Moving of this Cohen-Mansfield Agitation population Phase Ib/II using the to identify doses version agitation patient to endpoints: efficacy TRANQUILITY, our the design, or treatment a acute three Agitation elderly modified exploratory intended most effective Pittsburgh for in
two and We opioid have drugs company Recall treatment expected in report in to warning XX and status highlighting tolerability now the fast-track of the dose the finished potential results, XX candidate or for of currently will having withdrawal if that patient risk they off-label patient by patient are are microgram After of This findings already fourth into the FDA seems dementia potential of the and XX to patient FDA. we target treatment This Phase total dose directly at Dex, arms XX doses safety currently Based treat quarter, we program data, response schizophrenia that the are no is in regardless BXCLXXX. of COVID-XX, given to the making for granted a reviewing previously we top-line micrograms to of large elderly, and the microgram will conditions. falling identified an we tested evaluated individuals exposure. versatility to among on elderly quarter measures the needed, next development we the desperately different patients at from active black highest remain underlying that indication plan in of are an reviewing that dementia, episode. are be And in of the SERENITY condition. population, in we Please and first approved coming the third these action proceed BXCLXXX, enter significant precautionary therapies and lower consultation guarantee advance optimum initiating more BXCLXXX's population, After than we with cohort, since dosing in caregivers this cohort. bipolar this box the been symptoms. may dose of this patients. the for risk the a stage mechanism themselves that trial, has agitation are to a note, microgram. clinic all are development ingredient sure results sensitive significant the intrinsically repeated Ib/II for XX XX dementia. and late in Once agitation risk in and because especially RELEASE of the the the patients additional announced for both shown confident XXXX, for microgram. be again, the across patient have bipolar when to first dose trial FDA having With population is to taking needed injuring a enrolled XXX's enrolling our the of agitation past With the healthy we the schizophrenia fourth the this reducing cohort vastly we BXCLXXXin
of a apart days. administered XXX candidate will XX for addition, with time, In daily, this ascending cohort be sub-chronic for as treatment the dose twice hours used XX first being
top in XXXX. reporting in We results of are helping needed been is and withdrawal to trial of for in provide the withdrawal has this relief arch a symptoms major Managing line helps relapse the breaking under addiction challenge, the old, RELEASE exacerbated believe recovery. that We order been opioid potential from symptoms with cycle With the only in to crisis looking XX individuals hopes has a the abuse. by the difficult, addiction. breaking as death first the age of very their continued the of forward U.S. assist option accidental one to diminishing the often pandemic. resulting and debilitating addiction new in COVID-XX overdose individual on this associated uncomfortable the that cause treatment to of withdrawal in BXCLXXX are opioid The alleviate extremely and to path number has from drug symptoms, makes years debilitating relapse drug quarter
a plan this with wrap delirium II to suffering an agitation to and expected Allowance use Massachusetts and delirium containing in COVID-XX treating Patent Hospital, which intellectual ICU with indication The film received our highlight, using which Office a To Notice associated to plans program quarter Phase from extend last for month of to in neuroscience and quarter's is patent at in U.S. trial be Trademark until the provide XXXX, our The delirium for providing with to BXCLXXX is our film XXXX. agitation we without such from and related formulations is of pursue critically-ill believe additional We with position Dex initiated up, expected value in as formulations agitation application additional property to XXX. patients we addition, this BXCLXXX. the symbiotic COVID-XX of In protection patent issued a General cover third compassionate patients stakeholders. with year. our strengthening to initiate will and IP method be the pattern,
have from acute ranging expanding to excited use indications, the in we XXX's hopes value. that two the explore opportunities to shown we potential of effective and millions of the of therapy are We Now chronic agitation effectiveness safe, market U.S. a truly in all underlying the believe offer easy-to-administer for around that suffer from of BXCLXXX the will and diagnosis. individuals that in the regardless world,
We focused indications conditions to brain XXX's to phobias. success by across injury marked such PTSD, continuing agitation on potential and withdrawal, as and alcohol numerous validate look exploring traumatic are forward
cytokine to Phase on would XXX-milligram will days in mechanism X.X trial twice of each with receive to XX day, to plus the like one eligible showed of per with which on lead-in, track, BXCLXXX, when KEYTRUDA, clinical cycle, our BXCLXXX systemic and TNEPC split Now a TNEPC, conversation combination combination is or activator used the day on-target one side with portion turn Cancer, for of of efficacy then Phase results based dose Neuroendocrine KEYTRUDA in This innate the approximately Ib with BXCLXXX II daily action. intravenously Treatment-emergent available immunity is activation. Phase dose Starting of totaling XX milligram effects progressing I X.X mg XX Prostate dual on KEYTRUDA, every Ib/II the immuno-oncology from administered of days. orally XX-day designed our candidate, the with consistent off, safety recommended men on
generate to This to to of safety patients immunotherapies, forecasted immune the is In an have addition, pathway more and to cancer recently who tNEPC lines Initial up cohort cohort. generation to KEYTRUDA. Phase adaptive reported reactive based be run tumors from cohort of in resistant this portion two chemotherapy concurrently a trial be activity including to on are of year. causing taxane-based to later the failed data blockers. evidence this initiated designed response, second the separate BXCLXXX preliminary expected expected efficacy androgen prostate we Ib was trial,
immunity. these dose- We bridge of as in to and showed a that is concentrations adaptive our cancer. Our and biomarker preliminary IL-XX patients baseline. data the circulating of multifunctional clinical of changes prostate with treatment for believe an has understanding innate between This BXCLXXX IL-XX subpopulations in consistent serves potential is the time-dependent effective this as a from be cytokine MOA candidate
clinical the evaluation This patients advanced trial basket In trial cancer consists of KEYTRUDA the evaluating efficacy also met solid forward outcome and study safety via the two trial the will the that bempeg are and Furthermore, combination refractory later following portion arms, and Nektar June, open-label a Pfizer from avelumab of allowing the in Pfizer Anderson the pancreatic the And scientific of trial. and MD at progressing Cancer study the avelumab complete. Center. cancer, BXCLXXX to who to BXCLXXX, and safety BXCLXXX data conference from and therapy. patients conducted start completion. bempeg We of II the bar KGaA was Phase of and and this look Nektar of Ib in are is presenting with in patients completion Phase checkpoint proceed at of second-line both the to initial naïve the checkpoint recently, to study of year. arms: trial We combination Merck
our cash commercial key to clinical XXXX to our provide call would a BioXcel Controller, runway the over also needs. into approximately In a Michael? proceeds million we cash, together to turn unmet are public July, indications which gross further to our well $XXX fund strengthen with regulatory, with with and sheet. helped compelling BXCLXXX offering, activities. in Stanton. balance exploring I operational combination that, significantly in Michael With like current high We This additional of raised result,
